Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pasireotide + everolimus
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Peptides, Small Molecules
- Administration
- Intramuscular, Oral
01
Overview
Pasireotide + everolimus is a combination therapy of two pharmaceutical agents used primarily in the treatment of advanced neuroendocrine tumors (NETs), including pancreatic NETs, and has also been studied in other cancers such as hepatocellular carcinoma and medullary thyroid carcinoma. Pasireotide is a second-generation somatostatin analogue that binds to multiple somatostatin receptor subtypes, inhibiting hormone secretion and cell proliferation. Everolimus is an mTOR inhibitor that blocks the mammalian target of rapamycin pathway, leading to reduced cell growth, proliferation, angiogenesis, and glucose uptake. The combination aims for synergistic antiproliferative effects by dual inhibition of insulin-like growth factor 1 (IGF-1) signaling (via pasireotide) and mTOR signaling (via everolimus). Both drugs are developed by Novartis[2][3][1][8].
- Brand names
- SigniforAfinitor
- Other names
- pasireotide LAReverolimus LAR
02
Targets
FKBP1ASSTR3 (Somatostatin receptor 3)SSTR1 (Somatostatin Receptor Type 1)Mechanistic target of rapamycin complex 1SSTR2 (Somatostatin receptor type 2)SSTR5 (Somatostatin receptor 5)
Beyond the preview
Go deeper on pasireotide + everolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pasireotide + everolimus.